ClinicalTrials.gg
RecruitingNCT06618651Updated Nov 17, 2025

A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of SHR-3821 injection in Advanced Solid Tumors, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
162
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation and written .
  2. 18-75 years older, no gender limitation.
  3. (ECOG) score: 0-1.
  4. With a ≥ 3 months.
  5. diagnosed advanced solid tumor.
  6. Be able to provide fresh or archived tumour tissue.
  7. At least one according to v1.1.
  8. Adequate bone marrow reserve and organ function.
  9. is required during the trial.

Exclusion criteria

Exclusion Criteria:

  1. Meningeal history or clinical symptoms of central nervous system metastasis.
  2. Uncontrollable tumor-related pain.
  3. Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion with clinical symptoms.
  4. Received systemic antitumor therapy before the first dose.
  5. Treated with similar target therapy as SHR-3821 before the first dose.
  6. Received systemic anticancer treatments 4 weeks prior to the initiation of the study treatment.
  7. Unresolved 5.0>=grade 2 toxicities from previous anticancer therapy.
  8. Current or History of ILD.
  9. Active severe digestive disease.
  10. Previous or co-existing .
  11. History of severe reactions to either the drug substances or inactive ingredients of SHR-3821.
  12. Active or active .
  13. Other inappropriate situation considered by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    SHR-3821 injection

    Drug: SHR-3821 injection

Interventions

  • DrugSHR-3821 injection

    SHR-3821 injection

06

What researchers measure

Primary outcomes

  1. DLT

    Time frame: 3 weeks

  2. AE

    Time frame: Screening up to study completion, an average of 1 year

  3. MTD

    Time frame: 3 weeks

  4. RP2D

    Time frame: Screening up to study completion, an average of 1 year

Secondary outcomes

  1. Blood concentration of SHR-3821 after single and continuous administration

    Time frame: Screening up to study completion, an average of 1 year

  2. PK parameters of SHR-3821 after single and continuous administration: Tmax

    Time frame: Screening up to study completion, an average of 1 year

  3. PK parameters of SHR-3821 after single and continuous administration: Cmax

    Time frame: Screening up to study completion, an average of 1 year

  4. PK parameters of SHR-3821 after single and continuous administration: AUC0-t

    Time frame: Screening up to study completion, an average of 1 year

  5. Drug Resistant Antibody (ADA) to SHR-3821

    Time frame: Screening up to study completion, an average of 1 year

  6. Objective response rate (ORR)

    Time frame: Screening up to study completion, an average of 1 year

  7. Disease control rate (DCR)

    Time frame: Screening up to study completion, an average of 1 year

  8. Progression-free survival (PFS)

    Time frame: Screening up to study completion, an average of 1 year

  9. Overall survival (OS)

    Time frame: Screening up to study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
  • West China Hospital of Sichuan Hospital
    Chengdu, Sichuan 610000, China
    Recruiting
    • Jiankun Hu · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jan 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2024
First posted
Oct 1, 2024
StartActual
Nov 13, 2024
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jan 1, 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06618651
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Nov 13, 2024
Primary completion
Jan 1, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Bin bai
Contact
bin.bai@hengrui.com
+86 15618539080
Hao Shen
Contact
hao.shen@hengrui.com
+86 021-61053363

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion